JP2017529837A5 - - Google Patents

Download PDF

Info

Publication number
JP2017529837A5
JP2017529837A5 JP2017512760A JP2017512760A JP2017529837A5 JP 2017529837 A5 JP2017529837 A5 JP 2017529837A5 JP 2017512760 A JP2017512760 A JP 2017512760A JP 2017512760 A JP2017512760 A JP 2017512760A JP 2017529837 A5 JP2017529837 A5 JP 2017529837A5
Authority
JP
Japan
Prior art keywords
optionally substituted
group
independently
carbon atoms
branched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017512760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017529837A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/048044 external-priority patent/WO2016036794A1/en
Publication of JP2017529837A publication Critical patent/JP2017529837A/ja
Publication of JP2017529837A5 publication Critical patent/JP2017529837A5/ja
Pending legal-status Critical Current

Links

JP2017512760A 2014-09-03 2015-09-02 細胞結合剤及び細胞毒性剤を含む複合体 Pending JP2017529837A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462045264P 2014-09-03 2014-09-03
US62/045,264 2014-09-03
US201462086986P 2014-12-03 2014-12-03
US62/086,986 2014-12-03
US201562149379P 2015-04-17 2015-04-17
US62/149,379 2015-04-17
US201562186235P 2015-06-29 2015-06-29
US62/186,235 2015-06-29
PCT/US2015/048044 WO2016036794A1 (en) 2014-09-03 2015-09-02 Conjugates comprising cell-binding agents and cytotoxic agents

Publications (2)

Publication Number Publication Date
JP2017529837A JP2017529837A (ja) 2017-10-12
JP2017529837A5 true JP2017529837A5 (https=) 2018-10-11

Family

ID=54147280

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017512760A Pending JP2017529837A (ja) 2014-09-03 2015-09-02 細胞結合剤及び細胞毒性剤を含む複合体

Country Status (13)

Country Link
US (3) US10988531B2 (https=)
EP (1) EP3188733B1 (https=)
JP (1) JP2017529837A (https=)
KR (3) KR102638901B1 (https=)
CN (1) CN107580604A (https=)
AU (1) AU2015312075A1 (https=)
CA (1) CA2957964A1 (https=)
IL (1) IL250711A0 (https=)
MA (1) MA40415A (https=)
RU (1) RU2017110068A (https=)
SG (2) SG11201701565PA (https=)
TW (1) TW201609152A (https=)
WO (1) WO2016036794A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999604B (zh) * 2014-09-02 2021-08-03 伊缪诺金公司 用于配制抗体药物缀合物组合物的方法
TW201609152A (zh) 2014-09-03 2016-03-16 免疫原公司 包含細胞結合劑及細胞毒性劑之偶聯物
ES2815353T3 (es) * 2014-09-03 2021-03-29 Immunogen Inc Derivados de benzodiazepina citotóxicos
JP7297408B2 (ja) 2015-02-06 2023-06-26 セル アイディーエックス, インコーポレイテッド 抗原をカップリングさせた免疫試薬
ES2887273T3 (es) * 2015-06-29 2021-12-22 Immunogen Inc Anticuerpos anti-CD123 y conjugados y derivados de los mismos
SG10202106529XA (en) * 2015-07-21 2021-07-29 Immunogen Inc Methods of preparing cytotoxic benzodiazepine derivatives
MX2018009487A (es) * 2016-02-05 2019-01-31 Millennium Pharm Inc Conjugados de anticuerpo y fármaco dirigidos contra gcc.
TWI750194B (zh) * 2016-07-05 2021-12-21 大陸商江蘇恆瑞醫藥股份有限公司 Egfr抗體-藥物偶聯物及其在醫藥上的應用
JP7618383B2 (ja) * 2016-07-22 2025-01-21 ネクター セラピューティクス オキシム含有リンケージを有する第viii因子部分のコンジュゲート
AU2017355402A1 (en) * 2016-11-02 2019-05-30 Health Research, Inc. Combination treatment with antibody-drug conjugates and PARP inhibitors
EP3554544A4 (en) 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
SI3558391T1 (sl) * 2016-12-23 2022-06-30 Immunogen, Inc. Imunokonjugati, ciljno usmerjeni na ADAM9, in načini njihove uporabe
KR20250171447A (ko) * 2017-02-28 2025-12-08 이뮤노젠 아이엔씨 자기희생적 펩티드 링커 및 이들의 접합체를 갖는 메이탄시노이드 유도체
WO2018183494A1 (en) * 2017-03-31 2018-10-04 Immunogen, Inc. Cd19-targeting antibody-drug conjugates
EP3658568A4 (en) * 2017-07-26 2021-04-28 The University of Queensland Disulfide bond containing compounds and uses thereof
IL301637B2 (en) 2017-09-29 2024-10-01 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
EP3713962A4 (en) * 2017-11-21 2021-08-25 Novartis AG TRISPECIFIC BINDING MOLECULES AGAINST TUMOR-ASSOCIATED ANTIGENS AND THEIR USE
MA51629A (fr) * 2018-01-12 2020-11-18 Immunogen Inc Procédés de production, purification et formulation de conjugués anticorps-médicaments
CN115925952A (zh) 2018-03-13 2023-04-07 东莞凡恩世生物医药有限公司 抗叶酸受体1抗体及其用途
KR102821508B1 (ko) 2018-04-10 2025-06-16 셀렉타 바이오사이언시스, 인코퍼레이티드 인지질-플라베글린 접합체 및 표적화된 암 치료를 위해 이를 사용하는 방법
CN112955548B (zh) 2018-07-09 2023-11-24 普众发现医药科技(上海)有限公司 叶酸受体α特异性抗体
JP2022500454A (ja) * 2018-09-17 2022-01-04 ストロ バイオファーマ インコーポレーテッド 抗葉酸受容体抗体コンジュゲートによる併用療法
TWI897855B (zh) * 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途
WO2020092631A1 (en) * 2018-10-31 2020-05-07 Fred Hutchinson Cancer Research Center Compositions and methods for detecting and treating cancers characterized by expression of mesothelin
US20210032285A1 (en) * 2019-03-11 2021-02-04 Cell Idx, Inc. Methods, compositions, and kits for trapping modified biomolecules
CN120131907A (zh) 2019-03-19 2025-06-13 瓦尔希伯伦私人肿瘤研究基金会 采用Omomyc和结合PD-1或CTLA-4的抗体治疗癌症的联合疗法
US11833214B2 (en) * 2019-03-21 2023-12-05 Immunogen, Inc. Methods of preparing cell-binding agent-drug conjugates
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas
EP3972993A1 (en) 2019-05-21 2022-03-30 Novartis AG Variant cd58 domains and uses thereof
CA3154192A1 (en) 2019-10-10 2021-04-15 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
CN110922482B (zh) * 2019-12-25 2021-08-31 源道隆(苏州)医学科技有限公司 可结合cd19的多肽及其应用
CN112794911B (zh) * 2021-04-14 2021-08-03 上海偌妥生物科技有限公司 人源化抗叶酸受体1抗体及其应用
CN113908589B (zh) * 2021-10-08 2022-09-27 天津工业大学 一种表面印迹抗体的疏水电荷诱导模式膜层析介质及其制备方法
AU2023370106A1 (en) 2022-10-25 2025-05-08 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy for the treatment of cancer
EP4473974A1 (en) 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc and kras inhibitors combination therapy for the treatment of cancer
TW202513088A (zh) 2023-06-07 2025-04-01 瓦爾希伯倫私人腫瘤研究基金會 用於治療癌症的與mek抑制劑的組合療法
KR20260020418A (ko) 2023-06-07 2026-02-11 펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 데 발 헤브론 Braf 저해제를 이용한 암 치료용 조합 요법
CN117659041A (zh) * 2023-12-08 2024-03-08 联宁(苏州)生物制药有限公司 用于抗体偶联药物的氘代蒽环类毒素连接子及其合成方法和应用
KR20250146159A (ko) * 2024-03-29 2025-10-13 진메디신 주식회사 약물 및 항체를 연결하는 링커 화합물 및 이를 이용한 항체-약물 복합체

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
FR2801904B1 (fr) 1999-12-07 2002-02-08 Pasteur Institut Produits comprenant un support sur lequel sont fixes des acides nucleiques et leur utilisation comme puce a adn
CA2499496C (fr) 2002-09-19 2012-04-24 Centre National De La Recherche Scientifique - Cnrs Synthese et caracterisation de nouveaux systemes de guidage et de vectorisation de molecules d'interet therapeutique vers des cellules cibles
EA008866B1 (ru) 2002-12-26 2007-08-31 Маунтин Вью Фамэсьютикэлс, Инк. ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
KR20120064120A (ko) 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
WO2006042848A2 (en) 2004-10-18 2006-04-27 Novo Nordisk A/S Growth hormone conjugates
CA2600749C (en) 2005-03-10 2014-04-15 Nascacell Ip Gmbh Dimeric or multimeric microproteins
EP1877100A2 (en) 2005-04-25 2008-01-16 GE Healthcare AS Liposomes
JP4938263B2 (ja) * 2005-08-19 2012-05-23 独立行政法人農業生物資源研究所 一本鎖抗体によるサイトゾルタンパク質の機能阻害法およびその利用
WO2007048127A2 (en) 2005-10-20 2007-04-26 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
FR2897616B1 (fr) 2006-02-20 2008-05-30 Univ Grenoble 1 Presentation de motifs de reconnaissance par une matrice multivalente greffee sur un support solide
US7985783B2 (en) * 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
DK2474557T3 (da) 2007-07-16 2014-11-10 Genentech Inc Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
RU2476441C2 (ru) 2007-10-19 2013-02-27 Сиэтл Дженетикс, Инк. Cd19-связывающие средства и их применение
WO2009059278A1 (en) 2007-11-02 2009-05-07 Centocor, Inc. Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses
EP2276506A4 (en) 2008-04-30 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
CN103037900B (zh) * 2010-02-24 2016-04-06 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
US9381058B2 (en) * 2010-11-05 2016-07-05 Ethicon Endo-Surgery, Llc Recharge system for medical devices
JP6049642B2 (ja) * 2011-02-15 2016-12-21 イミュノジェン・インコーポレーテッド 複合体の調製方法
AU2013256596A1 (en) 2012-05-01 2014-10-09 Genentech, Inc. Anti-PMEL17 antibodies and immunoconjugates
EP2855521A4 (en) * 2012-05-24 2016-03-02 Mountgate Group Ltd COMPOSITIONS AND METHODS RELATED TO PREVENTING AND TREATING TOLL WUTINFECTION
JP6310909B2 (ja) 2012-06-06 2018-04-11 ビオノール イミュノ エーエスBionor Immuno As 免疫原及び投薬反応物として使用するためのウイルスタンパク質に由来するペプチド
US9834597B2 (en) 2012-09-21 2017-12-05 The Regents Of The University Of California Modified FC polypeptides, FC conjugates, and methods of use thereof
EP3300108B1 (en) * 2013-03-28 2019-07-24 Toshiba Hokuto Electronics Corporation Light emitting device and method for manufacturing the same
EP3001813B1 (en) 2013-05-13 2019-03-27 Vision Global Holdings Ltd. Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging
AU2014312086B2 (en) * 2013-08-30 2020-03-12 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
WO2015079376A1 (en) 2013-11-26 2015-06-04 Novartis Ag Methods for oxime conjugation to ketone-modified polypeptides
TW201609152A (zh) 2014-09-03 2016-03-16 免疫原公司 包含細胞結合劑及細胞毒性劑之偶聯物

Similar Documents

Publication Publication Date Title
JP2017529837A5 (https=)
RU2017110068A (ru) Конъюгаты, содержащие клеточносвязывающие агенты и цитотоксические агенты
JP7611218B2 (ja) 抗cd123抗体、ならびにその複合体及び誘導体
CN108290949B (zh) 对asct2具有特异性的结合分子及其用途
RU2017144859A (ru) Конъюгаты сконструированных антител с цистеиновыми заменами
TW202400644A (zh) 針對FRα之結合分子
AU2020414996A1 (en) Method for producing eribulin-based antibody-drug conjugate
US20230310629A1 (en) Bispecific antibody-drug conjugates targeting egfr and muc1 and uses thereof
US20230084099A1 (en) Anti-meflin antibody for use in treatment of cancer in subject having cancer, and pharmaceutical composition comprising the antibody
CN120417937A (zh) Ceacam5抗体-药物缀合物及其使用方法
KR20250172654A (ko) Steap2 항체 약물 접합체 및 이의 용도
EP2281004A1 (en) Prostate specific membrane antigen antibodies and antigen binding fragments
WO2024240227A1 (en) Antibodies and antibody-drug conjugates thereof
KR20260046386A (ko) 인간화 muc1 항체 및 항체 약물 접합체
CN120936386A (zh) 核定位多肽及其缀合物及其用途
Nguyen Development and Optimization of Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia
WO2026082125A1 (zh) 结合folr1的抗体、含有其的药物及其应用
HK40082538A (en) Method for producing eribulin-based antibody-drug conjugate